Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1996 • 535 citations

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1996 • 477 citations

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1998 • 408 citations

Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275

1994 • 349 citations

Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275

1992 • 344 citations

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy

1996 • 264 citations

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.

1997 • 261 citations

Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts

1998 • 246 citations

Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol

1998 • 225 citations

Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma

2001 • 205 citations

Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases

1988 • 193 citations

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

1996 • 190 citations

An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis

1988 • 152 citations

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

1997 • 141 citations

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

2000 • 131 citations

Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.

2000 • 78 citations

Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.

2001 • 44 citations

Targets for cancer therapy in the cell cycle pathway

1996 • 35 citations

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection

1998 • 21 citations